{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:14:39Z","timestamp":1783145679870,"version":"3.54.6"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-40923-7","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T22:19:05Z","timestamp":1771625945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Implementation of a 1021-gene liquid biopsy assay for real-world tumor genomic profiling in oncology practice"],"prefix":"10.1038","volume":"16","author":[{"given":"Chrysiida","family":"Florou-Chatzigiannidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Metaxa-Mariatou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Tsantikidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Maxouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsaousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Touroutoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Zairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nektarios","family":"Alevizopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinga Dan","family":"Corneliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iorga","family":"Polixenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Ozdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cemil","family":"Bilir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhan","family":"Hacibekiroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahin","family":"Lacin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Ajami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"El Hachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Nasioulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Bramis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manousos","family":"Konstadoulakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"4","key":"40923_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.annonc.2023.02.004","volume":"34","author":"O Amato","year":"2023","unstructured":"Amato, O., Aftimos, P. & Ignatiadis, M. Liquid biopsy accelerates precision medicine. Ann. Oncol. 34 (4), 333\u2013335 (2023).","journal-title":"Ann. Oncol."},{"key":"40923_CR2","doi-asserted-by":"crossref","unstructured":"Papadopoulou, E. et al. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients. PLoS One. ;14(12):e0226853. (2019). Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31860648","DOI":"10.1371\/journal.pone.0226853"},{"issue":"1","key":"40923_CR3","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma, L. et al. Liquid biopsy in cancer: current status, challenges and future prospects. Signal. Transduct. Target. Ther. 9 (1), 336 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"40923_CR4","doi-asserted-by":"publisher","first-page":"104776","DOI":"10.1016\/j.critrevonc.2025.104776","volume":"213","author":"R Borea","year":"2025","unstructured":"Borea, R. et al. Cancer in a drop: Advances in liquid biopsy in 2024. Crit. Rev. Oncol. Hematol. 213, 104776 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"40923_CR5","doi-asserted-by":"crossref","unstructured":"Smit, D. J. & Pantel, K. Circulating tumor cells as liquid biopsy markers in cancer patients. Mol Aspects Med. ; 96:101258. (2024). Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0098299724000177?via%3Dihub","DOI":"10.1016\/j.mam.2024.101258"},{"issue":"1","key":"40923_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41467-020-20162-8","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. Nat. Commun. 12 (1), 11 (2021).","journal-title":"Nat. Commun."},{"issue":"1","key":"40923_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41591-024-03244-8","volume":"31","author":"Y Nakamura","year":"2025","unstructured":"Nakamura, Y. et al. Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors. Nat. Med. 31 (1), 165\u2013175 (2025).","journal-title":"Nat. Med."},{"issue":"21","key":"40923_CR8","doi-asserted-by":"publisher","first-page":"eads5002","DOI":"10.1126\/sciadv.ads5002","volume":"11","author":"C Hruban","year":"2025","unstructured":"Hruban, C. et al. Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer. Sci. Adv. 11 (21), eads5002 (2025).","journal-title":"Sci. Adv."},{"issue":"3","key":"40923_CR9","doi-asserted-by":"publisher","first-page":"e1619","DOI":"10.1002\/ctm2.1619","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Longitudinal circulating tumour DNA dynamics predict failure patterns and efficacy of consolidation immunotherapy after chemoradiotherapy in locally advanced non-small-cell lung cancer. Clin. Transl Med. 14 (3), e1619 (2024).","journal-title":"Clin. Transl Med."},{"key":"40923_CR10","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.jlb.2023.100007","volume":"1","author":"C Parisi","year":"2023","unstructured":"Parisi, C. et al. Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications. J. Liquid Biopsy. 1, 100007 (2023).","journal-title":"J. Liquid Biopsy"},{"issue":"12","key":"40923_CR11","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","volume":"26","author":"Y Nakamura","year":"2020","unstructured":"Nakamura, Y. et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat. Med. 26 (12), 1859\u20131864 (2020).","journal-title":"Nat. Med."},{"key":"40923_CR12","doi-asserted-by":"publisher","first-page":"104613","DOI":"10.1016\/j.critrevonc.2025.104613","volume":"207","author":"J Song","year":"2025","unstructured":"Song, J., Ye, X. & Xiao, H. Liquid biopsy entering clinical practice: Past discoveries, current insights, and future innovations. Crit. Rev. Oncol. Hematol. 207, 104613 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"40923_CR13","doi-asserted-by":"crossref","unstructured":"Vellanki, P. J. et al. Regulatory implications of ctDNA in immuno-oncology for solid tumors. J. Immunother Cancer ;11(2). (2023).","DOI":"10.1136\/jitc-2022-005344"},{"key":"40923_CR14","doi-asserted-by":"publisher","first-page":"e2400354","DOI":"10.1200\/PO.24.00354","volume":"8","author":"J Fallah","year":"2024","unstructured":"Fallah, J. et al. False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations. JCO Precis Oncol. 8, e2400354 (2024).","journal-title":"JCO Precis Oncol."},{"issue":"8","key":"40923_CR15","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual, J. et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 33 (8), 750\u2013768 (2022).","journal-title":"Ann. Oncol."},{"issue":"6680","key":"40923_CR16","doi-asserted-by":"publisher","first-page":"eadf2341","DOI":"10.1126\/science.adf2341","volume":"383","author":"C Martin-Alonso","year":"2024","unstructured":"Martin-Alonso, C. et al. Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies. Science 383 (6680), eadf2341 (2024).","journal-title":"Science"},{"issue":"15","key":"40923_CR17","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","volume":"25","author":"NB Leighl","year":"2019","unstructured":"Leighl, N. B. et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin. Cancer Res. 25 (15), 4691\u20134700 (2019).","journal-title":"Clin. Cancer Res."},{"key":"40923_CR18","doi-asserted-by":"publisher","first-page":"e2400283","DOI":"10.1200\/PO.24.00283","volume":"9","author":"T Fujisawa","year":"2025","unstructured":"Fujisawa, T. et al. Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study. JCO Precis Oncol. 9, e2400283 (2025).","journal-title":"JCO Precis Oncol."},{"issue":"10","key":"40923_CR19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik, P. K. et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl. J. Med. 383 (10), 931\u2013943 (2020).","journal-title":"N Engl. J. Med."},{"issue":"20","key":"40923_CR20","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9, F. et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl. J. Med. 380 (20), 1929\u20131940 (2019).","journal-title":"N Engl. J. Med."},{"issue":"28","key":"40923_CR21","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard, F. C. et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J. Clin. Oncol. 40 (28), 3246\u20133256 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"40923_CR22","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner, N. C. et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl. J. Med. 388 (22), 2058\u20132070 (2023).","journal-title":"N Engl. J. Med."},{"issue":"3","key":"40923_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10549-024-07376-w","volume":"207","author":"MA Bhave","year":"2024","unstructured":"Bhave, M. A. et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res. Treat. 207 (3), 599\u2013609 (2024).","journal-title":"Breast Cancer Res. Treat."},{"issue":"9","key":"40923_CR24","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","volume":"9","author":"J Mazieres","year":"2023","unstructured":"Mazieres, J. et al. Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 9 (9), 1260\u20131266 (2023).","journal-title":"JAMA Oncol."},{"issue":"7","key":"40923_CR25","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1038\/s41591-024-03008-4","volume":"30","author":"S Peters","year":"2024","unstructured":"Peters, S. et al. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2\/3 BFAST trial. Nat. Med. 30 (7), 1923\u20131932 (2024).","journal-title":"Nat. Med."},{"issue":"1","key":"40923_CR26","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson, V. A. et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat. Commun. 8 (1), 1324 (2017).","journal-title":"Nat. Commun."},{"issue":"5","key":"40923_CR27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jmoldx.2025.02.005","volume":"27","author":"H Boulos","year":"2025","unstructured":"Boulos, H. et al. Analytical Validation of Next-Generation Sequencing\u2013Based Comprehensive Liquid Biopsy Assay for Therapy Selection. J. Mol. Diagn. 27 (5), 383\u2013394 (2025).","journal-title":"J. Mol. Diagn."},{"key":"40923_CR28","doi-asserted-by":"crossref","unstructured":"Meintani, A. et al. Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use. Int. J. Mol. Sci. ;26(13). (2025).","DOI":"10.3390\/ijms26135930"},{"issue":"3","key":"40923_CR29","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/annonc\/mdy513","volume":"30","author":"J Liu","year":"2019","unstructured":"Liu, J. et al. Biological background of the genomic variations of cf-DNA in healthy individuals. Ann. Oncol. 30 (3), 464\u2013470 (2019).","journal-title":"Ann. Oncol."},{"issue":"3","key":"40923_CR30","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74 (3), 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"issue":"14","key":"40923_CR31","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.3390\/cancers17142388","volume":"17","author":"I Attili","year":"2025","unstructured":"Attili, I., Fabrizio, F. P. & de Marinis, F. Co-Occurring Genomic Alterations in NSCLC: Making Order into a Crowded List. Cancers (Basel). 17 (14), 2388 (2025).","journal-title":"Cancers (Basel)"},{"issue":"21","key":"40923_CR32","doi-asserted-by":"publisher","first-page":"10366","DOI":"10.3390\/ijms262110366","volume":"26","author":"DP Narvaez","year":"2025","unstructured":"Narvaez, D. P. & Cescon, D. W. Navigating Treatment Sequencing in Advanced HR+\/HER2\u2009\u2013\u2009Breast Cancer After CDK4\/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies. Int. J. Mol. Sci. 26 (21), 10366 (2025).","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"40923_CR33","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jmoldx.2020.04.210","volume":"22","author":"Z Cai","year":"2020","unstructured":"Cai, Z. et al. Detection of Microsatellite Instability from Circulating Tumor DNA by Targeted Deep Sequencing. J. Mol. Diagn. 22 (7), 860\u2013870 (2020).","journal-title":"J. Mol. Diagn."},{"issue":"1","key":"40923_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12943-021-01479-4","volume":"21","author":"T Jiang","year":"2022","unstructured":"Jiang, T. et al. On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial. Mol. Cancer. 21 (1), 4 (2022).","journal-title":"Mol. Cancer"},{"key":"40923_CR35","doi-asserted-by":"publisher","first-page":"e2300654","DOI":"10.1200\/PO.23.00654","volume":"8","author":"G Vandekerkhove","year":"2024","unstructured":"Vandekerkhove, G. et al. Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer. JCO Precis Oncol. 8, e2300654 (2024).","journal-title":"JCO Precis Oncol."},{"key":"40923_CR36","doi-asserted-by":"publisher","first-page":"100170","DOI":"10.1016\/j.jlb.2024.100170","volume":"6","author":"M Izhar","year":"2024","unstructured":"Izhar, M., Ahmad, Z., Moazzam, M. & Jader, A. Targeted liquid biopsy for brain tumors. J. liquid biopsy. 6, 100170 (2024).","journal-title":"J. liquid biopsy"},{"issue":"3","key":"40923_CR37","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/2159-8290.CD-21-0450","volume":"12","author":"CF Friedman","year":"2022","unstructured":"Friedman, C. F. et al. Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. Cancer Discov. 12 (3), 654\u2013669 (2022).","journal-title":"Cancer Discov"},{"key":"40923_CR38","doi-asserted-by":"publisher","first-page":"102595","DOI":"10.1016\/j.ctrv.2023.102595","volume":"119","author":"R T\u00e9bar-Mart\u00ednez","year":"2023","unstructured":"T\u00e9bar-Mart\u00ednez, R. et al. Strategies for improving detection of circulating tumor DNA using next generation sequencing. Cancer Treat. Rev. 119, 102595 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"40923_CR39","doi-asserted-by":"crossref","unstructured":"Colosini, A. et al. Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study. Biomedicines ;10(6). (2022).","DOI":"10.3390\/biomedicines10061321"},{"issue":"4","key":"40923_CR40","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/s41591-023-02226-6","volume":"29","author":"ZJF Assaf","year":"2023","unstructured":"Assaf, Z. J. F. et al. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat. Med. 29 (4), 859\u2013868 (2023).","journal-title":"Nat. Med."},{"key":"40923_CR41","doi-asserted-by":"publisher","first-page":"1436588","DOI":"10.3389\/fonc.2024.1436588","volume":"14","author":"M Sposito","year":"2024","unstructured":"Sposito, M. et al. Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study. Front. Oncol. 14, 1436588 (2024).","journal-title":"Front. Oncol."},{"key":"40923_CR42","doi-asserted-by":"crossref","unstructured":"Nguyen Hoang, V. A. et al. Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid Tumors. JCO Oncol. Adv. ; (2025). (2).","DOI":"10.1200\/OA-24-00084"},{"issue":"3","key":"40923_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41416-021-01507-6","volume":"126","author":"G Marsavela","year":"2022","unstructured":"Marsavela, G. et al. Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. Br. J. Cancer. 126 (3), 401\u2013408 (2022).","journal-title":"Br. J. Cancer"},{"issue":"1","key":"40923_CR44","first-page":"63","volume":"4","author":"N Guo","year":"2024","unstructured":"Guo, N. et al. Circulating tumor DNA as prognostic markers of relapsed breast cancer: a systematic review and meta-analysis. J. Natl. Cancer Cent. 4 (1), 63\u201373 (2024).","journal-title":"J. Natl. Cancer Cent."},{"issue":"11","key":"40923_CR45","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","volume":"28","author":"J Jee","year":"2022","unstructured":"Jee, J. et al. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nat. Med. 28 (11), 2353\u20132363 (2022).","journal-title":"Nat. Med."},{"issue":"11","key":"40923_CR46","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jtho.2024.07.008","volume":"19","author":"JE Gray","year":"2024","unstructured":"Gray, J. E. et al. Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3. J. Thorac. Oncol. 19 (11), 1525\u20131538 (2024).","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"40923_CR47","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/gutjnl-2021-324852","volume":"71","author":"F Wang","year":"2022","unstructured":"Wang, F. et al. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut 71 (7), 1340\u20131349 (2022).","journal-title":"Gut"},{"key":"40923_CR48","doi-asserted-by":"publisher","first-page":"100003","DOI":"10.1016\/j.jlb.2023.100003","volume":"1","author":"S Mishima","year":"2023","unstructured":"Mishima, S. et al. Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN. J. liquid biopsy. 1, 100003 (2023).","journal-title":"J. liquid biopsy"},{"issue":"11","key":"40923_CR49","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-23-3321","volume":"30","author":"CD Rolfo","year":"2024","unstructured":"Rolfo, C. D. et al. Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation. Clin. Cancer Res. 30 (11), 2452\u20132460 (2024).","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"40923_CR50","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1158\/1078-0432.CCR-24-2105","volume":"30","author":"P Soberanis Pina","year":"2024","unstructured":"Soberanis Pina, P. et al. Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer. Clin. Cancer Res. 30 (24), 5657\u20135665 (2024).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"40923_CR51","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","volume":"15","author":"NM Fonseca","year":"2024","unstructured":"Fonseca, N. M. et al. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat. Commun. 15 (1), 1828 (2024).","journal-title":"Nat. Commun."},{"key":"40923_CR52","doi-asserted-by":"crossref","unstructured":"Lin, D. I., Pasquina, L. W., Mavares, E., Elvin, J. A. & Huang, R. S. P. Real-world pan-tumor comprehensive genomic profiling sample adequacy and success rates in tissue and liquid specimens. Oncologist ;30(2). (2025).","DOI":"10.1093\/oncolo\/oyae258"},{"issue":"1","key":"40923_CR53","doi-asserted-by":"publisher","first-page":"e2351700","DOI":"10.1001\/jamanetworkopen.2023.51700","volume":"7","author":"WT Iams","year":"2024","unstructured":"Iams, W. T. et al. Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort. JAMA Netw. Open. 7 (1), e2351700 (2024).","journal-title":"JAMA Netw. Open."},{"issue":"4","key":"40923_CR54","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jhep.2024.10.020","volume":"82","author":"S Hwang","year":"2025","unstructured":"Hwang, S. et al. Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer. J. Hepatol. 82 (4), 649\u2013657 (2025).","journal-title":"J. Hepatol."},{"issue":"2","key":"40923_CR55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jmoldx.2019.10.013","volume":"22","author":"J Jiang","year":"2020","unstructured":"Jiang, J. et al. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Cell-Free DNA in Stage I-IV Non-Small Cell Lung Cancer. J. Mol. Diagn. 22 (2), 228\u2013235 (2020).","journal-title":"J. Mol. Diagn."},{"issue":"12","key":"40923_CR56","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1038\/s41379-021-00880-0","volume":"34","author":"LH Lin","year":"2021","unstructured":"Lin, L. H. et al. Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas. Mod. Pathol. 34 (12), 2168\u20132174 (2021).","journal-title":"Mod. Pathol."},{"issue":"1","key":"40923_CR57","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13058-025-02055-0","volume":"27","author":"M Chaki","year":"2025","unstructured":"Chaki, M. et al. Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations. Breast Cancer Res. 27 (1), 122 (2025).","journal-title":"Breast Cancer Res."},{"issue":"1","key":"40923_CR58","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41467-024-47195-7","volume":"15","author":"AM Conway","year":"2024","unstructured":"Conway, A. M. et al. A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary. Nat. Commun. 15 (1), 3292 (2024).","journal-title":"Nat. Commun."},{"issue":"1","key":"40923_CR59","doi-asserted-by":"publisher","first-page":"101349","DOI":"10.1016\/j.xcrm.2023.101349","volume":"5","author":"N Moldovan","year":"2024","unstructured":"Moldovan, N. et al. Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis. Cell. Rep. Med. 5 (1), 101349 (2024).","journal-title":"Cell. Rep. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40923-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40923-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40923-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:05:37Z","timestamp":1774530337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40923-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40923"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40923-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10064"}}